SBI Okasan Asset Management Co.Ltd. Purchases Shares of 12,500 IQVIA Holdings Inc. $IQV

SBI Okasan Asset Management Co.Ltd. purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 12,500 shares of the medical research company’s stock, valued at approximately $2,839,000. IQVIA accounts for about 0.2% of SBI Okasan Asset Management Co.Ltd.’s portfolio, making the stock its 29th largest holding.

Other hedge funds also recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. purchased a new stake in IQVIA in the fourth quarter valued at $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA in the fourth quarter valued at $27,000. Activest Wealth Management boosted its holdings in IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 118 shares during the last quarter. Physician Wealth Advisors Inc. boosted its holdings in IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the last quarter. Finally, Westside Investment Management Inc. boosted its holdings in IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 101 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IQV has been the topic of several recent research reports. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a report on Friday, March 6th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and increased their target price for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Truist Financial lowered their target price on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Stifel Nicolaus lowered their target price on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Finally, Mizuho set a $215.00 target price on shares of IQVIA in a research note on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $225.69.

IQVIA Stock Up 9.2%

IQV opened at $180.92 on Friday. IQVIA Holdings Inc. has a twelve month low of $136.41 and a twelve month high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a 50-day moving average price of $170.04 and a 200 day moving average price of $196.28. The company has a market cap of $30.20 billion, a PE ratio of 22.42, a price-to-earnings-growth ratio of 1.58 and a beta of 1.18.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the prior year, the firm earned $2.70 EPS. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has approved a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.